Cempra (CEMP) : Traders are bullish on Cempra (CEMP) as it has outperformed the S&P 500 by a wide margin of 11.36% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 14.18%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 14.78% in the last 1 week, and is up 9.1% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 9.86% and the 50-Day Moving Average is 17.24%.The 200 Day SMA reached 23.28% Cempra, Inc. is up 35.29% in the last 3-month period. Year-to-Date the stock performance stands at -20.69%.
Cempra (CEMP) : Currently there are 10 street experts covering Cempra (CEMP) stock. The most bullish and bearish price target for the stock is $51 and $25 respectively for the short term. The average price target of all the analysts comes to $38.5. The estimated standard deviation from the target is $7.52.
For the current week, the company shares have a recommendation consensus of Buy. Cempra (NASDAQ:CEMP): stock was range-bound between the intraday low of $24.34 and the intraday high of $25.2 after having opened at $25.11 on Fridays session. The stock finally closed in the red at $25.11, a loss of -2.80%. The stock remained in the red for the whole trading day. The total traded volume was 1,531,600 shares. The stock failed to cross $25.2 in Fridays trading. The stocks closing price on Thursday was $24.69.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.